
CH4 Natural Solutions Corp
96
Recent news items from primary sources do not directly relate to CH4 Natural Solutions Corp or its business activities.
- No recent business-specific news coverage was identified for CH4 Natural Solutions Corp in the provided recent news dataset, limiting visibility into current company developments.
CH4 Natural Solutions Corp is a publicly listed company on the NYSE with multiple classes of shares and warrants. The company reported a net loss and has a shareholders' deficit as of the latest quarterly period ending March 31, 2026. It has no cash on hand and current liabilities exceed one million dollars. The company is classified as an emerging growth company and has disclosed substantial doubt about its ability to continue as a going concern due to insufficient working capital. There is no detailed public disclosure of its business model, industry, or operations in the available filings.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Not applicable due to limited disclosure and lack of detailed business information.
The company faces liquidity challenges with no cash and significant current liabilities as of March 31, 2026. It has reported net losses and a shareholders' deficit. The going concern disclosure indicates material uncertainty about its ability to continue operations without additional financing. Lack of disclosed revenue and operational details increases uncertainty about business viability.
There is insufficient public information to assess CH4 Natural Solutions Corp's competitive advantages or moat. The company has not disclosed its business segments, products, or market positioning in the available SEC filings or recent news.
• Liquidity Risk: The company has no cash and cash equivalents and current liabilities of approximately $1.48 million as of March 31, 2026, raising concerns about its ability to meet short-term obligations.
• Going Concern Risk: Management disclosed substantial doubt about the company's ability to continue as a going concern within one year due to insufficient working capital.
• Dependence on Sponsor Funding: The company intends to rely on working capital loans or capital contributions from its sponsor or affiliates, but there is no guarantee such funding will be available or timely.
• Limited Business Disclosure: Lack of detailed information about the company's business model, operations, and revenue sources limits transparency and increases investment risk.
Business trends: The company is in an early or uncertain stage with no disclosed revenue and ongoing net losses, facing liquidity challenges.
Execution milestones: Key milestones include managing liquidity through potential sponsor funding and addressing going concern uncertainties disclosed in the latest quarterly filing.
Key risks: Liquidity constraints, going concern doubts, dependence on sponsor financing, and lack of detailed business model disclosure increase operational and financial risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- CH4 Natural Solutions Corp is a public company listed on the New York Stock Exchange under the ticker MTNE.
- The company has Class A ordinary shares, Class B ordinary shares, and warrants listed on the NYSE.
- As of March 31, 2026, the company had 7,666,667 Class B ordinary shares issued and outstanding, after a share dividend and cancellation of founder shares.
- The company reported a net loss of $100,452 for the three months ended March 31, 2026, with basic and diluted net loss per Class B ordinary share of $0.02.
- As of March 31, 2026, the company had no cash and cash equivalents and current liabilities of $1,477,624, resulting in a cash ratio of 0.
- The company has a shareholders' deficit of $372,191 as of March 31, 2026.
- The company is classified as an emerging growth company and has elected to use the extended transition period for complying with new or revised financial accounting standards.
- The company disclosed substantial doubt about its ability to continue as a going concern within one year from the date of the financial statements, citing insufficient working capital to fund operating needs for at least one year.
- Management intends to address liquidity concerns through potential working capital loans or capital contributions from the sponsor or affiliates, but there is no assurance of availability or timing.
- The company has no reported revenue or segment information disclosed in the SEC filings.
- The recent news items provided do not relate directly to CH4 Natural Solutions Corp or its business activities.
Generated 2026-06-15
- S1 | 2026-06-12 | 10-Q
- N1 | 2026-06-15 | www.nasdaq.com | Edge Total Intelligence Wins $1.2 Mln Austal USA Contracts For U.S. Navy Platform | https://www.nasdaq.com/articles/edge-total-intelligence-wins-12-mln-austal-usa-contracts-us-navy-platform
- N2 | 2026-06-15 | www.nasdaq.com | DAX Up 1.2% As Stocks Rally On U.S.-Iran Peace Deal | https://www.nasdaq.com/articles/dax-12-stocks-rally-us-iran-peace-deal
- N3 | 2026-06-15 | www.nasdaq.com | Mineralys Reports Lorundrostat Reduced Heart Failure Risk Biomarkers In Hypertension Trials | https://www.nasdaq.com/articles/mineralys-reports-lorundrostat-reduced-heart-failure-risk-biomarkers-hypertension-trials
- N4 | 2026-06-15 | www.nasdaq.com | Are You Collecting All the Social Security You're Due? | https://www.nasdaq.com/articles/are-you-collecting-all-social-security-youre-due
- N5 | 2026-06-15 | www.nasdaq.com | Oil Prices Hit Three-month Low On US-Iran Deal | https://www.nasdaq.com/articles/oil-prices-hit-three-month-low-us-iran-deal
- N6 | 2026-06-15 | www.nasdaq.com | Dollarama Fiscal Q1 Earnings Call Sticks With Growth Plan | https://www.nasdaq.com/articles/dollarama-fiscal-q1-earnings-call-sticks-growth-plan
- N7 | 2026-06-15 | www.nasdaq.com | Rhythm Reports Positive Preliminary Phase 2 Data For Setmelanotide In Treating Prader-Willi | https://www.nasdaq.com/articles/rhythm-reports-positive-preliminary-phase-2-data-setmelanotide-treating-prader-willi
- N8 | 2026-06-15 | www.nasdaq.com | Bayer Receives FDA Approval For AMBELVIST For Contrast-Enhanced MRI | https://www.nasdaq.com/articles/bayer-receives-fda-approval-ambelvist-contrast-enhanced-mri
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


